ATE348152T1 - Verfahren zum screening von diabetes- heilverfahren - Google Patents

Verfahren zum screening von diabetes- heilverfahren

Info

Publication number
ATE348152T1
ATE348152T1 AT01998193T AT01998193T ATE348152T1 AT E348152 T1 ATE348152 T1 AT E348152T1 AT 01998193 T AT01998193 T AT 01998193T AT 01998193 T AT01998193 T AT 01998193T AT E348152 T1 ATE348152 T1 AT E348152T1
Authority
AT
Austria
Prior art keywords
screening diabetes
cure
diabetes cure
screening
cell
Prior art date
Application number
AT01998193T
Other languages
English (en)
Inventor
Takahide Ohishi
Jun Takasaki
Mitsuyuki Matsumoto
Chou-Ku
Tetsu Saito
Masazumi Kamohara
Takatoshi Soga
Shigeru Yoshida
Yoshitaka Ueda
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26605096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE348152(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Application granted granted Critical
Publication of ATE348152T1 publication Critical patent/ATE348152T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT01998193T 2000-12-01 2001-11-30 Verfahren zum screening von diabetes- heilverfahren ATE348152T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000367349 2000-12-01
JP2001243841 2001-08-10

Publications (1)

Publication Number Publication Date
ATE348152T1 true ATE348152T1 (de) 2007-01-15

Family

ID=26605096

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01998193T ATE348152T1 (de) 2000-12-01 2001-11-30 Verfahren zum screening von diabetes- heilverfahren

Country Status (8)

Country Link
US (3) US20030180813A1 (de)
EP (2) EP1770159A1 (de)
JP (1) JP3438186B2 (de)
AT (1) ATE348152T1 (de)
AU (1) AU2002218509A1 (de)
DE (1) DE60125227T2 (de)
ES (1) ES2280435T3 (de)
WO (1) WO2002044362A1 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE42190E1 (en) 1998-11-20 2011-03-01 Arena Pharmaceuticals, Inc. Method of identifying a compound for inhibiting or stimulating human G protein-coupled receptors
US7816492B2 (en) * 1998-11-20 2010-10-19 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors
US20030017528A1 (en) 1998-11-20 2003-01-23 Ruoping Chen Human orphan G protein-coupled receptors
US20030125539A1 (en) * 1999-02-22 2003-07-03 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
JP2002130117A (ja) * 2000-10-18 2002-05-09 Mikuni Corp 電磁駆動型プランジャポンプ
WO2002044362A1 (en) * 2000-12-01 2002-06-06 Yamanouchi Pharmaceutical Co., Ltd. Method of screening remedy for diabetes
GB0031527D0 (en) * 2000-12-22 2001-02-07 Smithkline Beecham Plc New use
US7241579B2 (en) 2000-12-22 2007-07-10 Smithkline Beecham Corporation Method of screening for GPR40 ligands
US20050191612A1 (en) * 2002-09-11 2005-09-01 Takahide Ohishi Method of screening insulin content enhancer
ES2295816T3 (es) 2003-01-14 2008-04-16 Arena Pharmaceuticals, Inc. Derivados arilo y heteroarilo 1,2,3-trisustituidos como moduladores del metabolismo, y profilaxis y tratamiento de transtornos relacionados con los mismos, tales como la diabetes y la hiperglucemia.
JPWO2004084944A1 (ja) * 2003-03-25 2006-06-29 住友製薬株式会社 新規血糖調節薬及びそのスクリーニング方法
US7083933B1 (en) 2003-05-09 2006-08-01 Prosidion Limited Methods for identification of modulators of OSGPR116 activity
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
WO2005009469A1 (ja) * 2003-07-28 2005-02-03 Sumitomo Pharmaceuticals Co., Ltd. 新規血糖調節薬及びそのスクリーニング方法
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
US7833730B2 (en) 2006-04-11 2010-11-16 Arena Pharmaceuticals, Inc. Methods of using GPR119 to identify compounds useful for increasing bone mass in an individual
CN101754961A (zh) * 2007-04-20 2010-06-23 先灵公司 嘧啶酮衍生物及其使用方法
CA2684633A1 (en) * 2007-04-20 2008-10-30 Schering Corporation Pyrimidinone derivatives and methods of use thereof
ES2388967T3 (es) 2007-05-04 2012-10-22 Bristol-Myers Squibb Company Agonistas [6,6]- y [6,7]-bicíclicos del receptor GPR119 acoplado a la proteína G
EP2152707B1 (de) 2007-05-04 2012-06-20 Bristol-Myers Squibb Company An gpr119-g-protein gekoppelte [6,5]-bicyclische rezeptoragonisten
JP5318867B2 (ja) 2007-07-17 2013-10-16 ブリストル−マイヤーズ スクイブ カンパニー ピリドンｇｐｒ１１９ｇタンパク質共役受容体アゴニスト
MX2010004450A (es) 2007-10-22 2010-05-05 Schering Corp Derivados heterociclo biciclicos y su uso como moduladores de la actividad de gpr119.
EP2146210A1 (de) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Verfahren zur Verwendung eines AG-Protein-gekoppelten Rezeptors zur Identifikation von Peptid-YY (PPY)-Sekretagogen sowie Verbindungen zur Behandlung durch PYY modulierter Leiden
CA2724426A1 (en) 2008-05-19 2009-11-26 Schering Corporation Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
JP2011528365A (ja) 2008-07-16 2011-11-17 シェーリング コーポレイション Ｇｐｒ１１９モジュレーターとしての二環式ヘテロ環誘導体およびそれらの使用方法
JP2011528369A (ja) 2008-07-16 2011-11-17 シェーリング コーポレイション 二環式ヘテロ環誘導体およびそれらの使用方法
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
US8722882B2 (en) 2008-12-23 2014-05-13 Merck Sharp & Dohme Corp. Pyrimidine derivatives as GPCR modulators for use in the treatment of obesity and diabetes
WO2010075273A1 (en) 2008-12-23 2010-07-01 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
JP2012513470A (ja) 2008-12-23 2012-06-14 シェーリング コーポレイション 二環式複素環誘導体及びその使用方法
AR076024A1 (es) 2009-04-03 2011-05-11 Schering Corp Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos
US8580807B2 (en) 2009-04-03 2013-11-12 Merck Sharp & Dohme Corp. Bicyclic piperidine and piperazine derivatives as GPCR modulators for the treatment of obesity, diabetes and other metabolic disorders
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
WO2011053688A1 (en) 2009-10-29 2011-05-05 Schering Corporation Bridged bicyclic piperidine derivatives and methods of use thereof
US8912206B2 (en) 2009-11-23 2014-12-16 Merck Sharp & Dohme Corp. Pyrimidine ether derivatives and methods of use thereof
US20120232073A1 (en) 2009-11-23 2012-09-13 Santhosh Francis Neelamkavil Fused bicyclic pyrimidine derivatives and methods of use thereof
US9301929B2 (en) 2009-11-24 2016-04-05 Merck Sharp & Dohme Corp. Substituted biaryl derivatives and methods of use thereof
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
JP2013523819A (ja) 2010-04-06 2013-06-17 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置
CN102933576A (zh) 2010-04-08 2013-02-13 百时美施贵宝公司 作为gpr119调节剂的嘧啶基哌啶基氧基吡啶酮类似物
BR112012028445A2 (pt) 2010-05-06 2016-07-19 Bristol Myers Squibb Co compostos de heteroarila bicíclica como moduladores de gpr119
US8729084B2 (en) 2010-05-06 2014-05-20 Bristol-Myers Squibb Company Benzofuranyl analogues as GPR119 modulators
EP2619198A1 (de) 2010-09-22 2013-07-31 Arena Pharmaceuticals, Inc. Modulatoren des gpr119-rezeptors und behandlung von damit assoziierten erkrankungen
WO2012115640A1 (en) * 2011-02-23 2012-08-30 Elona Biotechnologies Liquid insulin- containing compositions and methods of making the same
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
ES2602813T3 (es) 2011-06-09 2017-02-22 Rhizen Pharmaceuticals S.A. Nuevos compuestos como moduladores de GPR-119
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2850073B1 (de) 2012-05-16 2017-07-19 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridon-analoga als gpr119-modulatoren
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
WO2016049200A1 (en) * 2014-09-24 2016-03-31 University Of Oregon Proteins increasing pancreatic beta cell number and methods of use
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
AU2018220521A1 (en) 2017-02-16 2019-09-05 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
KR102859841B1 (ko) 2018-06-06 2025-09-12 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 병태의 치료 방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL126750C (de) * 1960-12-05
DE3530767A1 (de) * 1985-08-28 1987-03-12 Max Planck Gesellschaft Mittel gegen multiple sklerose
IT1256191B (it) * 1992-12-03 1995-11-29 Impiego di lisolecitine nel trattamento della impotenza maschile e dell'alopecia e relative composizioni atte a tale impiego.
NZ510712A (en) 1998-10-13 2004-11-26 Arena Pharm Inc Non-endogenous, constitutively activated human G protein-coupled receptors
EP2295573A1 (de) 1998-11-20 2011-03-16 Arena Pharmaceuticals, Inc. Menschliche, an ein G-Protein gekoppelte Rezeptoren ohne bekannte Liganden
US20030017528A1 (en) * 1998-11-20 2003-01-23 Ruoping Chen Human orphan G protein-coupled receptors
EP1161242A4 (de) * 1999-01-29 2004-06-30 Beyer Camille F Zusammenstellungen und methoden zur behandlung von diabetes
US6221660B1 (en) * 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
GB9923177D0 (en) * 1999-09-30 1999-12-01 Pfizer Ltd Novel polypeptide
WO2001032864A2 (en) * 1999-11-03 2001-05-10 Merck Patent Gmbh Gpcr-kd5 polypeptides and dna sequences thereof
WO2001036473A2 (en) 1999-11-16 2001-05-25 Pharmacia & Upjohn Company Human g protein-coupled receptors
WO2001042288A2 (en) 1999-12-10 2001-06-14 Incyte Genomics, Inc. G-protein coupled receptors
WO2001087929A2 (en) * 2000-05-18 2001-11-22 Bayer Aktiengesellschaft Regulation of human dopamine-like g protein-coupled receptor
US20040067499A1 (en) * 2000-08-04 2004-04-08 Tatsuya Haga Novel g protein-coupled receptor
WO2002044362A1 (en) 2000-12-01 2002-06-06 Yamanouchi Pharmaceutical Co., Ltd. Method of screening remedy for diabetes
WO2002061087A2 (en) 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
WO2002064789A1 (en) 2001-02-14 2002-08-22 Pharmacia & Upjohn Company Protein-coupled receptor

Also Published As

Publication number Publication date
US20050136484A1 (en) 2005-06-23
WO2002044362A1 (en) 2002-06-06
EP1338651A1 (de) 2003-08-27
DE60125227D1 (de) 2007-01-25
US20030180813A1 (en) 2003-09-25
EP1770159A1 (de) 2007-04-04
DE60125227T2 (de) 2007-09-20
AU2002218509A1 (en) 2002-06-11
EP1338651B9 (de) 2007-05-09
ES2280435T3 (es) 2007-09-16
US20100144677A1 (en) 2010-06-10
EP1338651A4 (de) 2005-04-27
JP3438186B2 (ja) 2003-08-18
EP1338651B1 (de) 2006-12-13
US7662775B2 (en) 2010-02-16
JPWO2002044362A1 (ja) 2004-04-02

Similar Documents

Publication Publication Date Title
ATE348152T1 (de) Verfahren zum screening von diabetes- heilverfahren
DE59008475D1 (de) Verwendung eines schwer löslichen Salzes einer Heteropolysäure zur Bestimmung eines Analyts, entsprechendes Bestimmungsverfahren sowie hierfür geeignetes Mittel.
ATE110415T1 (de) Verbessertes verfahren und apparat, um biologische substanzen in lebenden zellen einzuführen.
GB8906181D0 (en) Process for the production of porous membranes,the membranes produced thereby and their use as supporting matrices in test strips
PT88183A (pt) Sensor of the enzime electrode type and process for realize analysis using that sensor
DE69229174D1 (de) Verwendung von haloalkylderivaten von reportermolekülen zur analyse der metabolischen aktivität in zellen
ATE332387T1 (de) Vorrichtung und verfahren zur einbringung von substanzen in eine zelle durch elektroporation
DE60325482D1 (de) Verfahren zur charakterisierung von biomolekülen mittels resultat-gesteuerter strategie
DE69427255D1 (de) Herstellung von Tetrazolium-Salz-Indikatoren enthaltenden diagnostischen Teststreifen
DE3788388D1 (de) Verfahren zur Herstellung eines REFETs oder eines CHEMFETs, sowie deren Herstellung.
ATE177434T1 (de) Antikoagulierende zusammensetzung
NO20064451L (no) fremgangsmate for maling av glykatert protein
DE60141129D1 (de) Hochdruckamboss und optisches fenster
DE69924975D1 (de) Verfahren und kit, um biologische substanzen in plasmamembran und/oder zytosol einzuführen
DE60236530D1 (de) Verfahren zur vorbehandlung von proben zur bestimmung von verzuckerten aminen, sowie verfahren zur bestimmung von verzuckerten aminen
AU2003302816A1 (en) Method for manufacturing tool for analysis
ATE483975T1 (de) Behälter und kits zur bestimmung von zellfunktionen und verfahren zu deren bestimmung
DE68921374D1 (de) Monoklonaler Antikörper gegen menschliche Mangan-Superoxiddismutase, Verfahren zu dessen Herstellung, Testreagens, Kit und Testmethode unter Verwendung desselben, Verfahren zur Diagnose von menschlichem Eierstockkrebs und von Herzinfarkt.
ATE534903T1 (de) Latex-reaktionsmittel zur adiponectinanalyse und verfahren zur adiponectinanalyse
ATE142332T1 (de) Verfahren zum sichten von zellen oder geformten körpern mit ausgewählten eigenschaften unter benutzung eines nachweisparameters
SE437303B (sv) Forfarande for on-line-metning av koncentrationen av en analyt i en behallare, samt apparat for genomforande av forfarandet
ES2089132T3 (es) Analisis de pelo.
ATE222954T1 (de) Verfahren zur herstellung von dem anaphase- fördernden komplex
CA2004068A1 (en) Hair analysis method
Tsuda et al. A new type of N-nitrosamino acid, N-nitroso-L-thioproline and N-nitroso-L-methylthioprolines, found in human urine as major N-nitroso compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1338651

Country of ref document: EP